Picard Medical, Inc. Common Stock Overview
Industry: Surgical & Medical Instruments & Apparatus
Sector: Healthcare
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia To
Verified company profile, price history, and SEC registration source are available.
10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.
Review the SEC registration filingResearch snapshot
This Mavefund research page organizes verified information for Picard Medical, Inc. Common Stock (PMI), including the company profile, price history, source-linked filings, available financial statements, research signals, and risks to review.
- Listing
- PMI · NYSE · MIC XNYS
- Country
- United States
- Trading currency
- USD
- Industry
- Surgical & Medical Instruments & Apparatus
Coverage is refreshed automatically and published only after data-integrity validation. Research support only; not personalized financial advice.
Reported Results
No latest earnings report cached yet
The latest source-linked annual or interim company filing has not been cached for this ticker yet.
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
No qualified company news in the last 14 days
No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.
Financial Statements
Company-reported filing facts, organized and linked to the original source.
Source details load with the filing data. Values are standardized company disclosures for research support, not personalized financial advice.